1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
VivoSim Labs, Inc.

VivoSim Labs, Inc.

VIVS
VivoSim Labs, Inc.US flagNASDAQ
0.95
USD
-0.04
- -
2.48MMarket Cap
VivoSim Labs, Inc.
VIVS
(NASDAQ)

Recent

price

0.95

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
6.66
1.24
1.72
3.85
10.38
10.3
6.43
4.07
- -
2.07
0.51
0.14
0.1
0.06
Revenue per Share
-0.49
-242.24
-84.82
-90.64
-100.2
-94.38
-77.89
-55.4
-34.66
-29.25
-15.78
-23.77
-19.25
-1.7
-0.48
Basic EPS, GAAP
-0.46
-55.9
-51.97
-63.63
-81.87
-74.97
-65.24
-42.55
-27.57
-23.87
-12.22
-17.63
-19.28
-6.47
-4.13
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.62
-279.14
-302.33
-368.25
-417.64
-489.05
-523.69
-542.14
-517.69
-515.12
-424.28
-447.59
-445.71
-233.77
-136.16
Book Value per Share
-0.02
-29.5
158.44
146.73
161.52
153.09
99.78
75.5
49.33
68.15
41.65
21.11
4.73
7.17
1.73
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
3
Basic Weighted Avg Shares
- -
1
- -
1
1
4
5
3
2
- -
2
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
-778.53
-5,448.28
-5,305.95
-2,605.73
-911.94
-766.26
-882.37
-977.91
- -
-765.27
-4,792.16
-13,840.37
-8,761.11
-8,066.2
Operating Margin (%)
- -
- -
- -
- -
1
1
1
1
1
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-44
-26
-30
-39
-38
-35
-27
-19
-17
-11
-17
-15
-2
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-3,638.51
-6,820.05
-5,268.3
-2,601.15
-908.91
-756.09
-861.7
-852
- -
-763.2
-4,664.59
-13,459.63
-1,727.78
-864.08
Profit Margin (%)
- -
-6
47
47
59
59
42
35
27
38
28
13
2
8
4
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
1
1
- -
- -
LT Debt
- -
-5
48
49
62
62
45
36
27
39
30
15
4
10
4
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.73
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
3
6
5

Working Capital

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
Total Current Assets
10
8
6
Cash, Cash Equivalents & STI
9
7
4
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
1
1
1
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.41%
17.97%
191.36%
Free Cash Flow
-3.5%
-3.9%
-35.53%
Net Income, GAAP
-12.41%
-17.86%
-83.04%
Sales/Revenue/Turnover
- -
- -
32.11%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-5.54
-5.5
-4.74
- -
-19.25
2025
-2.74
-1.7
-2.29
- -
-1.7
2026
-1.14
-0.98
-1.03
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
BerGenBio ASA (BRRGF)
Lineage Cell Therapeutics, Inc. (LCTX.TA)
BioVie Inc. (BIVI)
GenSight Biologics S.A. (GSGTF)
CEL-SCI Corporation (CVM)
Compugen Ltd. (CGEN)
Business
I did not find relevant results on recent major changes specifically for VivoSim Labs, Inc. (Ticker: VIVS) in the initial search. I will conduct a more targeted search using the company name and ticker specifically with focus on products, latest offerings, partnerships, and corporate news.

Company News

APIChatGPT

  • globenewswire.com

    VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

  • globenewswire.com

    VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

  • globenewswire.com

    VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing

  • defenseworld.net

    Short Interest in VivoSim Labs, Inc. (NASDAQ:VIVS) Decreases By 69.3%

  • globenewswire.com

    VivoSim Announces Pricing of up to a $4 Million Public Offering

  • defenseworld.net

    Head-To-Head Analysis: Agenus (NASDAQ:AGEN) and VivoSim Labs (NASDAQ:VIVS)

  • globenewswire.com

    VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

  • defenseworld.net

    VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Update

  • globenewswire.com

    VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales

  • defenseworld.net

    VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Significant Decline in Short Interest

  • globenewswire.com

    VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

  • globenewswire.com

    VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China

  • defenseworld.net

    Analyzing Bristol Myers Squibb (NYSE:BMY) & VivoSim Labs (NASDAQ:VIVS)

  • defenseworld.net

    VivoSim Labs (NASDAQ:VIVS) and MediciNova (NASDAQ:MNOV) Head-To-Head Analysis

  • globenewswire.com

    VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer

  • globenewswire.com

    VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

  • seekingalpha.com

    I Missed The Quantum Rally - I Won't Miss The Next One

  • globenewswire.com

    VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

  • globenewswire.com

    VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market